Mepolizumab (n = 5) | Placebo (n = 6) | |
Mean age (years) | 32.4 | 34.0 |
Males (%) | 80 | 50 |
Caucasians (%) | 100 | 100 |
Mean weight (kg) | 74.0 | 75.3 |
Duration of EoO (years) | 5.32 | 5.28 |
Age of onset (years) | 26.6 | 28.7 |
Atopic disease at screen | ||
Asthma (n (%)) | 1 (20%) | 2 (33%) |
Eczema (n (%)) | 1 (20%) | 0 |
Food allergy (n (%)) | 1 (20%) | 0 |
Rhinitis (n (%)) | 4 (80%) | 4 (67%) |
Mean peak oesophageal eosinophils at screening (per hpf) | 201 | 202 |
EoO, eosinophilic oesophagitis; hpf, high power field.